MedTrace Logo

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

NCT01924793 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2017-07-19

No results posted yet for this study

Summary

This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection.

All subjects will have additional PK and Immunogenicity blood samples collected.

Conditions

  • Parainfluenza

Interventions

DRUG

DAS181-F02 Dry Powder in Bulk

Administered via DPI

DRUG

DAS181-F02 Nebulized Formulation Inhaled Dose

Administered via Nebulizer

Sponsors & Collaborators

  • Ansun Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Ron Moss, MD, CEO · Ansun Biopharma, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01924793 on ClinicalTrials.gov